Xeltis is one of three Swiss Medtech Award finalists; the only therapeutic medical device company to reach the final selection stage this year. The winner will be announced on June 12, as part of Swiss Medtech Day in Bern.
The Swiss Medtech award recognizes outstanding achievements in the Swiss medical technology industry. The criteria for nomination include, among others, the development of ground-breaking technologies or processes.
“We are proud to be among the last finalists for this high-profile award. This accolade recognizes the potential of our restorative device to make a difference in the lives of children born with congenital heart disease,” said Xeltis CEO Laurent Grandidier. He will introduce Xeltis to the 600 attendees before the announcement of the award winner.
Xeltis’ restorative heart valves are designed to enable the patient’s body to form a new valve with its own tissue. This novel approach in heart valve therapy may help reduce the risk of further interventions and it is currently being assessed in Europe, Asia and in the USA as part of clinical trials. Click here for more information on the Swiss Medtech Award.
